Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Straumann

Showing results (51-60 of 175) with videos related to

Pageof 18
Sort By:
Digestive Diseases and Sciences|April 15, 2019
Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and VedolizumabTanja Grandinetti, Luc Biedermann, Christian Bussmann, et al.
Clinical and Translational Gastroenterology|February 26, 2019
Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis- Current Concepts and Perspectives for Steroid UseThomas Greuter, Jeffrey A Alexander, Alex Straumann, et al.
The Journal of Allergy and Clinical Immunology|August 6, 2008
Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitisAlex Straumann, Christian Bussmann, Sébastien Conus, et al.
Digestion|February 1, 2013
Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymesKarin Dilger, Luis Lopez-Lazaro, Claudia Marx, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|October 5, 2020
How to approach adult patients with asymptomatic esophageal eosinophiliaPhilipp Schreiner, Luc Biedermann, Thomas Greuter, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 22, 2022
Natural History of Patients Lost to Follow-up After Esophageal Food ImpactionFritz Ruprecht Murray, Andrea Kreienbühl, Alex Straumann, et al.
Allergy|February 8, 2025
A Distinct Genetic Signature Differentiates Inflamed and Noninflamed Fibrotic Tissues in Eosinophilic Esophagitis PatientsEmilie Gueguen, Yasser Morsy, Luc Biedermann, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 25, 2025
Open-label, phase 2a pilot study evaluating the efficacy and tolerability of topical mesalamine treatment in adult patients with active eosinophilic esophagitisThomas Greuter, Alex Straumann, Andrea Kreienbühl, et al.
Therapeutic Advances in Gastroenterology|June 23, 2020
Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidenceStephan Miehlke, Alfredo J Lucendo, Alex Straumann, et al.
Journal of Crohn'S & Colitis|March 9, 2012
Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkersAlain M Schoepfer, Stephan Vavricka, Nadine Zahnd-Straumann, et al.
Pageof 18

Showing results (51-60 of 175) with videos related to

Sort By:
Pageof 18
Digestive Diseases and Sciences|April 15, 2019
Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and VedolizumabTanja Grandinetti, Luc Biedermann, Christian Bussmann, et al.
Clinical and Translational Gastroenterology|February 26, 2019
Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis- Current Concepts and Perspectives for Steroid UseThomas Greuter, Jeffrey A Alexander, Alex Straumann, et al.
The Journal of Allergy and Clinical Immunology|August 6, 2008
Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitisAlex Straumann, Christian Bussmann, Sébastien Conus, et al.
Digestion|February 1, 2013
Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymesKarin Dilger, Luis Lopez-Lazaro, Claudia Marx, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|October 5, 2020
How to approach adult patients with asymptomatic esophageal eosinophiliaPhilipp Schreiner, Luc Biedermann, Thomas Greuter, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 22, 2022
Natural History of Patients Lost to Follow-up After Esophageal Food ImpactionFritz Ruprecht Murray, Andrea Kreienbühl, Alex Straumann, et al.
Allergy|February 8, 2025
A Distinct Genetic Signature Differentiates Inflamed and Noninflamed Fibrotic Tissues in Eosinophilic Esophagitis PatientsEmilie Gueguen, Yasser Morsy, Luc Biedermann, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 25, 2025
Open-label, phase 2a pilot study evaluating the efficacy and tolerability of topical mesalamine treatment in adult patients with active eosinophilic esophagitisThomas Greuter, Alex Straumann, Andrea Kreienbühl, et al.
Therapeutic Advances in Gastroenterology|June 23, 2020
Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidenceStephan Miehlke, Alfredo J Lucendo, Alex Straumann, et al.
Journal of Crohn'S & Colitis|March 9, 2012
Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkersAlain M Schoepfer, Stephan Vavricka, Nadine Zahnd-Straumann, et al.
Pageof 18